secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001193125-25-146994
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies screens first subject in Phase 3 COMFORT Toddlers study for Viaskin Peanut
--------------------------------------------------------------------------------

- First subject screened at Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein as PI.
- Study to enroll ~480 subjects at 80-90 centers across U.S., Canada, Australia, UK, and Europe.
- BLA submission to FDA anticipated in 2H 2026 under Accelerated Approval Pathway.
- Study supplements safety data from Phase 3 EPITOPE; 6-month DBPC phase + optional 18-month open-label.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525146994/0001193125-25-146994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525146994/d51953d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-146994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer